Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Mcmurray, J, Laakso, M, Standl, E, Tognoni, G, Holman, R, Giles, T, Martinez, F, Thomas, L, Haffner, S, Califf, R
Formáid:	Journal article
Foilsithe / Cruthaithe:	2011

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
de réir: Preiss, D, et al.
Foilsithe / Cruthaithe: (2013)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
de réir: Preiss, D, et al.
Foilsithe / Cruthaithe: (2012)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
de réir: Califf, R, et al.
Foilsithe / Cruthaithe: (2008)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
de réir: Krum, H, et al.
Foilsithe / Cruthaithe: (2010)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
de réir: Latini, R, et al.
Foilsithe / Cruthaithe: (2013)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
de réir: Sharma, A, et al.
Foilsithe / Cruthaithe: (2016)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
de réir: Currie, G, et al.
Foilsithe / Cruthaithe: (2017)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
de réir: Califf, R, et al.
Foilsithe / Cruthaithe: (2003)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
de réir: Yates, T, et al.
Foilsithe / Cruthaithe: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
de réir: Yates, T, et al.
Foilsithe / Cruthaithe: (2014)

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
de réir: Holman, R, et al.
Foilsithe / Cruthaithe: (2010)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
de réir: Bales, C, et al.
Foilsithe / Cruthaithe: (2013)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
de réir: McMurray, J, et al.
Foilsithe / Cruthaithe: (2004)

The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in Type 2 diabetes
de réir: Mohanlal, N, et al.
Foilsithe / Cruthaithe: (2002)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
de réir: Shen, L, et al.
Foilsithe / Cruthaithe: (2012)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
de réir: Bethel, M, et al.
Foilsithe / Cruthaithe: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
de réir: Bethel, M, et al.
Foilsithe / Cruthaithe: (2013)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
de réir: Shen, L, et al.
Foilsithe / Cruthaithe: (2013)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
de réir: Bethel, A, et al.
Foilsithe / Cruthaithe: (2005)

Effect of Valsartan on the Incidence of Diabetes REPLY
de réir: Holman, R, et al.
Foilsithe / Cruthaithe: (2010)

Prediabetes and the risk of diabetes.
de réir: McMurray, J, et al.
Foilsithe / Cruthaithe: (2012)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
de réir: Holman, R, et al.
Foilsithe / Cruthaithe: (2003)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
de réir: Dos Santos, M, et al.
Foilsithe / Cruthaithe: (2017)

Effects of Glucose Load and Nateglinide Intervention on Endothelial Function and Oxidative Stress
de réir: Leilei Wang, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
de réir: Mcmurray, J, et al.
Foilsithe / Cruthaithe: (2012)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
de réir: Wamil, M, et al.
Foilsithe / Cruthaithe: (2020)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
de réir: de Barros e Silva, P, et al.
Foilsithe / Cruthaithe: (2014)

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
de réir: Stevens, R, et al.
Foilsithe / Cruthaithe: (2004)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
de réir: McMurray, J, et al.
Foilsithe / Cruthaithe: (2012)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
de réir: Marilia Harumi Higuchi dos Santos, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
de réir: Kraus, W, et al.
Foilsithe / Cruthaithe: (2012)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
de réir: Gerstein, H, et al.
Foilsithe / Cruthaithe: (2006)

Effect of valsartan on the incidence of diabetes and cardiovascular events.
de réir: McMurray, J, et al.
Foilsithe / Cruthaithe: (2010)

Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study
de réir: Preiss, D, et al.
Foilsithe / Cruthaithe: (2014)

Fatalism in systematic aspect and fatalism in its functional context
de réir: Gustav Henningsen
Foilsithe / Cruthaithe: (1967-01-01)

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
de réir: Preiss, D, et al.
Foilsithe / Cruthaithe: (2014)

Fatalism and Savings
de réir: Shapiro, J
Foilsithe / Cruthaithe: (2011)

Fatal voyage /
de réir: 374399 Reichs, Kathy
Foilsithe / Cruthaithe: (2001)

Fatal embrace /
de réir: 510932 Whittier, Aris
Foilsithe / Cruthaithe: (2005)

Fatal incomprehension
de réir: McLoughlin, K
Foilsithe / Cruthaithe: (2018)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Míreanna comhchosúla

Míreanna comhchosúla